Patent · US Active

Using nucleic acids encoding NAP-2 and TGF-alpha polypeptides to improve cardiac function

US9884090B2 · kind B2 · utility

0Cited by

0References

6Claims

0Family size

Assignee

Mayo Foundation for Medical Education and Research · US

Inventors

Atta Behfar · Rochester, US
Andre Terzic · Rochester, US
Ruben Jose Crespo-Diaz · Rochester, US

Key dates

Filing date	Sep 3, 2014
Grant date	Feb 6, 2018
Priority date	—
Expiry date	Sep 3, 2034

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/50
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk of experiencing a major adverse cardiac event as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI)) are provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.